Education
About Us
Working with TipRanks
Follow Us
Biovica International AB Class B (DE:9II)
FRANKFURT:9II
9II Stock Chart & Stats
€0.02
-€0.05(-28.13%)
At close: 4:00 PM EST
€0.02
-€0.05(-28.13%)
Day’s Range― - ―
52-Week Range€0.01 - €0.15
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€11.22M
Enterprise Value-€18.83M
Total Cash (Recent Filing)€100.66M
Total Debt (Recent Filing)€3.04M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Mar 18, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding275,289,060
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.50
Price to Sales (P/S)7.52
P/FCF Ratio-0.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Rapid Revenue GrowthSustained high trailing revenue growth indicates improving commercial traction for DiviTum and broader customer adoption. Over 2-6 months this momentum can materially improve scale economics, supporting investment in operations and increasing bargaining power with labs and pharma partners if growth persists.
Low Financial LeverageVery low debt reduces near-term liquidity risk and preserves financial flexibility, enabling management to prioritize commercial expansion or R&D without immediate debt servicing pressure. This structural balance-sheet strength lowers default risk and supports financing options over the medium term.
Specialized Oncology Diagnostic PlatformA focused, proprietary DiviTum biomarker platform creates durable differentiation in oncology monitoring. Niche expertise and clinical integration can generate recurring testing revenue, clinical-trial collaborations, and barriers to entry, supporting steady demand and longer-term commercial partnerships with healthcare providers and pharma.
Bears Say
Negative Gross ProfitA negative TTM gross profit signals that core unit economics are currently unprofitable, which is structurally unsustainable. Unless product costs or pricing improve, the business will struggle to convert revenue growth into operating profits, prolonging the need for external capital and limiting reinvestment capacity.
Heavy Cash BurnLarge, persistent negative operating and free cash flow increases dependency on external financing. This structural cash burn elevates dilution risk and constrains long-term investments in commercialization or R&D, forcing trade-offs that can slow sustainable margin expansion and market penetration.
Deep Negative Returns And Dilution RiskExtremely negative ROE reflects large accumulated losses versus equity and signals that shareholder value is being eroded. Volatile equity and continued losses imply likely future financing rounds, potentially diluting holders and complicating long-term investor confidence and capital access for strategic initiatives.
Biovica International AB Class B News
9II FAQ
What was Biovica International AB Class B’s price range in the past 12 months?
Biovica International AB Class B lowest stock price was €0.01 and its highest was €0.15 in the past 12 months.
What is Biovica International AB Class B’s market cap?
Biovica International AB Class B’s market cap is €11.22M.
When is Biovica International AB Class B’s upcoming earnings report date?
Biovica International AB Class B’s upcoming earnings report date is Mar 18, 2026 which is in 27 days.
How were Biovica International AB Class B’s earnings last quarter?
Biovica International AB Class B released its earnings results on Dec 18, 2025. The company reported -€0.005 earnings per share for the quarter, beating the consensus estimate of -€0.008 by €0.002.
Is Biovica International AB Class B overvalued?
According to Wall Street analysts Biovica International AB Class B’s price is currently Overvalued.
Does Biovica International AB Class B pay dividends?
Biovica International AB Class B does not currently pay dividends.
What is Biovica International AB Class B’s EPS estimate?
Biovica International AB Class B’s EPS estimate is >-0.01.
How many shares outstanding does Biovica International AB Class B have?
Biovica International AB Class B has 275,289,060 shares outstanding.
What happened to Biovica International AB Class B’s price movement after its last earnings report?
Biovica International AB Class B reported an EPS of -€0.005 in its last earnings report, beating expectations of -€0.008. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biovica International AB Class B?
Currently, no hedge funds are holding shares in DE:9II
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biovica International AB Class B
Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Technical Analysis
Alzinova AB
―
Biosergen AB
―
Nanologica AB
―
Lipigon Pharmaceuticals AB
―
NextCell Pharma AB
―